Logo

AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancer

Share this

AstraZeneca Reports Results of Imfinzi (durvalumab) + Tremelimumab in P-III NEPTUNE Study for Stage IV Non-Small Cell Lung Cancer

Shots:

  • The P-III NEPTUNE study involves assessing of Imfinzi + tremelimumab vs SOC platinum-based CT as a 1L treatment in patients with Stage IV metastatic NSCLC + high tumor mutational burden (TMB) across 29 countries including the US- Europe- South and Central America- the Middle East and Asia.
  • The P-III NEPTUNE study results demonstrated that it did not meet 1EPs i.e- OS in patients with high blood TMB defined as ≥ 20 mut/Mb while its safety and tolerability profile is consistent with previous studies
  • Imfinzi is a mAb targeting PD-L1- blocking its interaction with PD-1 and CD80- currently being evaluated in P-III PEARL study as monothx. and in combination with CT with/out tremelimumab in the P-III POSEIDON for Stage IV NSCLC

Click here to­ read full press release/ article

Ref: AstraZeneca | Image: AstraZeneca 


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions